From the Street:

MannKind Corporation (MNKD) - FREE Research Report

Pfeffer Matthew J who is Corporate VP and CFO at MANNKIND CORP sold 10,000 shares at $7.00 per share for a total value of $70,000.00 on July 2, 2013. Following this transaction, the Corporate VP and CFO owned 83,654 shares meaning that the stake was reduced by 10.68% with the 10,000 share sell-off.

The shares most recently traded at $6.93, up $0.06, or 0.87% since the insider transaction. Historical insider transactions for MannKind Corporation go as follows:

• 4-Week # shares bought: 9,058

• 4-Week # shares sold: 10,000

• 12-Week # shares bought: 9,058

• 12-Week # shares sold: 36,829

• 24-Week # shares bought: 9,058

• 24-Week # shares sold: 36,829

The average volume for MannKind Corporation has been 8.1 million shares per day over the past 30 days. MannKind Corporation has a market cap of $2.1 billion and is part of the health care sector and drugs industry. Shares are up 212.99% year to date as of the close of trading on Wednesday.

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. Currently there are 3 analysts that rate MannKind Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

http://www.thestreet.com/story/11970254/2/insider-trading-alert--chesapeake-energy-and-3-others-traded-by-insiders.html